MGO One Seven LLC Sells 34,062 Shares of Pfizer Inc. $PFE

MGO One Seven LLC cut its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 28.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 84,163 shares of the biopharmaceutical company's stock after selling 34,062 shares during the quarter. MGO One Seven LLC's holdings in Pfizer were worth $2,040,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of the stock. Brighton Jones LLC lifted its holdings in shares of Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after acquiring an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC lifted its holdings in shares of Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after acquiring an additional 2,087 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Pfizer by 69.0% in the 1st quarter. GAMMA Investing LLC now owns 63,131 shares of the biopharmaceutical company's stock worth $1,600,000 after acquiring an additional 25,785 shares during the last quarter. Elevation Point Wealth Partners LLC lifted its holdings in shares of Pfizer by 15.9% in the 1st quarter. Elevation Point Wealth Partners LLC now owns 16,809 shares of the biopharmaceutical company's stock worth $426,000 after acquiring an additional 2,311 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Pfizer by 55.3% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 2,606,123 shares of the biopharmaceutical company's stock worth $66,039,000 after acquiring an additional 928,180 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Down 0.8%

Shares of Pfizer stock opened at $24.53 on Wednesday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The company's fifty day simple moving average is $24.88 and its two-hundred day simple moving average is $24.12. The company has a market cap of $139.44 billion, a P/E ratio of 13.05, a PEG ratio of 0.82 and a beta of 0.55. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $29.82.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company's quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer's payout ratio is presently 91.49%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Bank of America boosted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock a "neutral" rating in a report on Friday, October 3rd. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Pfizer in a research note on Wednesday, October 8th. Wall Street Zen downgraded shares of Pfizer from a "buy" rating to a "hold" rating in a research note on Sunday, September 28th. UBS Group reaffirmed a "neutral" rating and issued a $28.00 target price on shares of Pfizer in a research note on Wednesday, October 1st. Finally, Citigroup lifted their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Pfizer currently has an average rating of "Hold" and an average target price of $28.35.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.